Novel Therapeutic Approaches in the Treatment of Multiple Myeloma

MMRF and New York Medical College
Last Modified: August 31, 2005

Share article


Conference Dates: September 30th, 2005
Conference Location: Marriott Marquis, 1535 Broadway, New York, NY

Sponsoring Group: MMRF and New York Medical College

Conference Web Page URL: www.nymc.edu/cme/upcoming_events.asp

Who Should Attend: Patients, Caregivers, Hematologists, Medical Oncologists, Oncology Nurses, Internists with recently diagnosed patients

Conference Agenda: Professional Program and Patient Program

Registration Information: Please contact the MMRF for more information. 203-972-1250

Conference Fees: $25

Continuing Education: Yes


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Jul 30, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More